Correlation between serum tumor abnormal protein expression and chemotherapeutic effect in patients with lung adenocarcinoma
10.3760/cma.j.issn.1006-9801.2018.01.007
- VernacularTitle:肺腺癌患者血清肿瘤异常蛋白表达与化疗效果的相关性
- Author:
Shuqin ZHANG
1
;
Wei MA
;
Xiaomin FENG
;
Bai WEI
Author Information
1. 华中科技大学同济医学院附属梨园医院肿瘤科
- Keywords:
Lung neoplasms;
Adenocarcinoma;
Tumor abnormal protein;
Antigens;
tumor-associated;
Treatment outcome
- From:
Cancer Research and Clinic
2018;30(1):34-37
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the correlation between serum tumor abnormal protein (TAP) a nd chemotherapeutic effect in patients with lung adenocarcinoma. Methods A prospective study was conducted on 90 patients with lung adenocarcinoma Liyuan Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology from May 2012 to April 2016. The patients were divided into adjuvant chemotherapy group (30 cases) and palliative chemotherapy group (60 cases) according to the different treatment regimen. The adjuvant chemotherapy group was treated with FOLFOX regimen for postoperative adjuvant chemotherapy. The palliative chemotherapy group was treated with pemetrexed. The t test was used to compare the expression levels of TAP in both groups. The χ2 test was used to compare the relationship among expression of TAP, the positive results of tumor markers and the efficacy of chemotherapy. Pearson correlation analysis was used to analyze the expression level of TAP and changes of tumor markers. Results There was no statistically significant difference in serum TAP between the two groups before palliative chemotherapy [area of TAP condensed matter were (230±80)μm2 and (206±50) μm2, t=1.487, P<0.05]. The serum TAP expression in both groups was 100％. There was no statistically significant difference in serum TAP area between adjuvant chemotherapy group and palliative chemotherapy group (46.7 ％ vs. 48.3％, χ2= 0.022, P> 0.05). There was no statistically significant difference between the two groups in positive expression of tumor markers CA125, CEA, CA19-9 and ALP (χ2 values were 4.02, 3.81, 4.01, 5.01, all P>0.05). In the two groups, the changes of serum TAP before and after chemotherapy had no relationship with age, gender, pathological differentiation degree and the number of transfer viscera (all P>0.05). The expression of serum TAP, CEA and CA19-9 after chemotherapy in palliative chemotherapy group were related to the efficacy of chemotherapy (χ2=6.62, 7.78, 8.62, all P<0.01). Pearson correlation analysis showed that the changes of serum TAP in palliative chemotherapy group had no relationship with tumor markers CA125, CEA, CA19-9 and ALP (r values were 0.42, 0.19, 0.09, 0.28, all P> 0.05). The serum TAP level of the adjuvant chemotherapy group was positively correlated with the level of tumor marker CA125 (r=0.51, P=0.02), with no correlation with the changes of CEA, CA19-9 and ALP levels (r values were 0.20, 0.24, 0.19, all P>0.05). Conclusion The detection of serum TAP level in patients with lung adenocarcinoma has good accuracy and high sensitivity, which indicates that the serum level of TAP in patients with lung adenocarcinoma before and after chemotherapy can be used as an index to evaluate the efficacy of chemotherapy and an independent detection of lung adenocarcinoma.
